BIOJAPAN 2026 will take place from October 7–9, 2026, at Pacifico Yokohama, bringing together pharmaceutical companies, biotechnology companies, research institutions, investors, and industry leaders from Japan and around the world to explore the latest innovations and collaboration opportunities across the life sciences industry.
With a strong focus on innovation and international collaboration, BIOJAPAN provides an ideal platform for connecting global partners and advancing new opportunities in drug discovery and development.
Date: October 7–9, 2026
Venue: Pacifico Yokohama, Japan
Medicilon Booth: D-20
Meet Medicilon at BIOJAPAN 2026
Medicilon will showcase its integrated preclinical R&D capabilities and innovative technology platforms, supporting drug development programs across multiple therapeutic modalities.
Key Areas:
- Small Molecule Drug Development
- ADC/AOC
- PROTAC
- Oligonucleotide Therapeutics
- Cell & Gene Therapy (CGT)
- Preclinical Safety Assessment
- Pharmaceutical Research & Development
AI-Driven + Organoid + Integrated Dry-Wet NAMs Platform
Medicilon continues to advance its AI-driven + organoid + integrated dry-wet NAMs (New Approach Methodologies) platform, integrating emerging technologies to support more efficient and innovative approaches to preclinical drug development.
The platform encompasses AI-enabled drug discovery, organoid and organ-on-chip technologies, PBPK modeling, and in vitro toxicology, providing diverse strategies for evaluating drug candidates and supporting translational research.
From Target to IND
As a full-service preclinical CRO, Medicilon provides integrated support spanning drug discovery, pharmaceutical research, preclinical research, and IND submission support, helping innovative drug developers advance programs efficiently through critical stages of development.
With extensive experience supporting global drug development programs, Medicilon has contributed to more than 690 IND approvals across projects submitted to regulatory authorities in China and overseas.
In addition, Medicilon has supported more than 20 overseas licensing deals for innovative drugs, further demonstrating its experience in supporting global drug development and international collaboration.
With capabilities covering multiple drug modalities and a broad range of preclinical services, Medicilon is committed to supporting partners throughout their drug development journey—from Target to IND.
Meet Our Team On Site
- Dr. Miao Yu (DVM) – Senior Director, Pathology, Medicilon
- Mr. Junhong Xu – Vice President of Business Development, Medicilon
Our team will be available at Booth D-20 to discuss your preclinical development needs, research strategies, and potential collaboration opportunities.
Connect with Medicilon in Yokohama
BIOJAPAN 2026 is an opportunity to connect with innovators across the global life sciences ecosystem.
Whether you are advancing a small molecule, ADC/AOC, PROTAC, oligonucleotide, or CGT program, we welcome the opportunity to discuss how Medicilon’s integrated preclinical capabilities can support your development strategy.
Visit Medicilon at Booth D-20 and let’s explore new possibilities for global drug development together.
From Target to IND, empowering innovative drug development.
